Free Trial

Iradimed (IRMD) Stock Price, News & Analysis

-0.57 (-1.29%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
23,233 shs
Average Volume
55,376 shs
Market Capitalization
$551.22 million
P/E Ratio
Dividend Yield
Price Target

Iradimed MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
43.5% Upside
$62.50 Price Target
Short Interest
1.30% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From $1.41 to $1.71 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

4th out of 920 stocks

Surgical & Medical Instruments Industry

1st out of 96 stocks

IRMD stock logo

About Iradimed Stock (NASDAQ:IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRMD Stock Price History

IRMD Stock News Headlines

iRadimed Q1 2024 Earnings Preview
IRMD Jul 2024 60.000 call
iRadimed Corp.
Should You Invest in IRadimed Corporation (IRMD)?
IRMD Mar 2024 45.000 put
IRMD Mar 2024 40.000 call
IRMD Feb 2024 44.520 call
IRadimed: Q4 Earnings Snapshot
See More Headlines
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 5/30 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$17.19 million
Pretax Margin


Sales & Book Value

Annual Sales
$65.56 million
Cash Flow
$1.42 per share
Book Value
$6.01 per share


Free Float
Market Cap
$551.22 million
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Roger E. Susi (Age 71)
    Founder, Chairman, CEO & President
    Comp: $642.57k
  • Mr. John F. Glenn (Age 62)
    CFO & Corporate Secretary
    Comp: $541.71k
  • Mr. Randy Waddell
    Vice President of Worldwide Sales & Marketing
  • Mr. Chris Williamson
    Executive Vice President of Continuous Improvement & Information Technology
  • Mr. Matt Garner
  • Mr. Steve Kachelmeyer
    Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Lynn Neuhardt
    Vice President of Research & Development

IRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Iradimed stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings
or view top-rated stocks.

What is Iradimed's stock price target for 2024?

3 brokers have issued twelve-month target prices for Iradimed's shares. Their IRMD share price targets range from $60.00 to $65.00. On average, they anticipate the company's stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 43.5% from the stock's current price.
View analysts price targets for IRMD
or view top-rated stocks among Wall Street analysts.

How have IRMD shares performed in 2024?

Iradimed's stock was trading at $47.47 at the start of the year. Since then, IRMD shares have decreased by 8.3% and is now trading at $43.54.
View the best growth stocks for 2024 here

When is Iradimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our IRMD earnings forecast

How were Iradimed's earnings last quarter?

Iradimed Corporation (NASDAQ:IRMD) released its quarterly earnings data on Thursday, October, 28th. The medical equipment provider reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. The medical equipment provider had revenue of $10.91 million for the quarter, compared to analyst estimates of $10.39 million. Iradimed had a net margin of 26.48% and a trailing twelve-month return on equity of 24.63%. During the same quarter last year, the company earned $0.09 earnings per share.

How often does Iradimed pay dividends? What is the dividend yield for Iradimed?

Iradimed declared a quarterly dividend on Thursday, May 2nd. Stockholders of record on Monday, May 20th will be paid a dividend of $0.15 per share on Thursday, May 30th. This represents a $0.60 annualized dividend and a yield of 1.38%. The ex-dividend date is Friday, May 17th.
Read our dividend analysis for IRMD

Is Iradimed a good dividend stock?

Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.36%. The dividend payout ratio is 42.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, IRMD will have a dividend payout ratio of 35.09% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for IRMD.

What ETF holds Iradimed's stock?

Ballast Small/Mid Cap ETF holds 30,576 shares of IRMD stock, representing 0.93% of its portfolio.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of 0.360-0.390 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $17.6 million-$17.8 million, compared to the consensus revenue estimate of $17.9 million.

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.37%), Bares Capital Management Inc. (2.20%), Russell Investments Group Ltd. (1.32%), Acadian Asset Management LLC (1.24%), Hillsdale Investment Management Inc. (0.77%) and Isthmus Partners LLC (0.57%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends

How do I buy shares of Iradimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRMD) was last updated on 5/23/2024 by Staff

From Our Partners